Valion Bio
VBIO
7 hedge funds and large institutions have $492K invested in Valion Bio in 2021 Q4 according to their latest regulatory filings, with 7 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0% more ownership
Funds ownership: 0% → 0% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KC
Kepos Capital
New York
|
+$257K |
| 2 |
E
Ergoteles
New York
|
+$73.3K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$66K |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
+$44K |
| 5 |
BlackRock
New York
|
+$36.7K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
KC
1
Kepos Capital
New York
| $233K | +$257K | +35 | New |
|
|
E
2
Ergoteles
New York
| $68K | +$73.3K | +10 | New |
|
|
3
Vanguard Group
Malvern,
Pennsylvania
| $60K | +$66K | +9 | New |
|
|
SSA
4
Schonfeld Strategic Advisors
New York
| $42K | +$44K | +6 | New |
|
|
5
BlackRock
New York
| $35K | +$36.7K | +5 | New |
|
6
Osaic Holdings
Scottsdale,
Arizona
| $35K | +$36.7K | +5 | New |
|
7
UBS Group
Zurich,
Switzerland
| $18K | +$22K | +3 | New |
|
|
TFS
8
TrustCore Financial Services
Brentwood,
Tennessee
| $1K | – | – | – |
|
VBIO Hedge Fund Activity: Q4 2021 in Review
7 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Valion Bio (VBIO) for Q4 2021, worth a combined $492K.
Buyers outnumbered sellers: 7 funds opened new VBIO positions and 0 closed out — a net gain of 7 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Kepos Capital, opening a new position worth an estimated $257K.
- 7 institutional investors held Valion Bio (VBIO) as of Q4 2021, up from 0 in Q3 2021.
- Funds reported $492K of Valion Bio stock for Q4 2021.
- 7 funds opened new Valion Bio positions in Q4 2021 and 0 closed out, a net change of +7 holders.
- The largest Valion Bio buyer in Q4 2021 was Kepos Capital, an estimated $257K added.
Based on aggregated 13F filings for Q4 2021.